Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.
2.

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A.

J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.

3.

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E, Graillon T, Gentet JC, Delattre O, Chinot O, Padovani L.

Oncotarget. 2018 Jan 3;9(11):10175-10183. doi: 10.18632/oncotarget.23699. eCollection 2018 Feb 9.

4.

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.

Kieran MW, Chisholm J, Casanova M, Brandes AA, Aerts I, Bouffet E, Bailey S, Leary S, MacDonald TJ, Mechinaud F, Cohen KJ, Riccardi R, Mason W, Hargrave D, Kalambakas S, Deshpande P, Tai F, Hurh E, Geoerger B.

Neuro Oncol. 2017 Oct 19;19(11):1542-1552. doi: 10.1093/neuonc/nox109.

5.

Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.

Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW.

Cancers (Basel). 2016 Feb 15;8(2). pii: E22. doi: 10.3390/cancers8020022. Review.

6.

L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo.

Zhu M, Wang H, Wang C, Fang Y, Zhu T, Zhao W, Dong X, Zhang X.

Front Pharmacol. 2019 Feb 21;10:89. doi: 10.3389/fphar.2019.00089. eCollection 2019.

7.

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.

Jain S, Song R, Xie J.

Onco Targets Ther. 2017 Mar 16;10:1645-1653. doi: 10.2147/OTT.S130910. eCollection 2017. Review.

8.

Traitement médical des carcinomes basocellulaires avancés: Medical treatment of advanced basal cell carcinoma.

Basset-Seguin N.

Ann Dermatol Venereol. 2018 Nov;145 Suppl 5:VS36-VS41. doi: 10.1016/S0151-9638(18)31257-2. Review. French.

PMID:
30477683
9.

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.

Li QR, Zhao H, Zhang XS, Lang H, Yu K.

Acta Pharmacol Sin. 2019 Feb;40(2):257-267. doi: 10.1038/s41401-018-0019-5. Epub 2018 May 18.

PMID:
29777201
10.

Targeted treatment for sonic hedgehog-dependent medulloblastoma.

Kieran MW.

Neuro Oncol. 2014 Aug;16(8):1037-47. doi: 10.1093/neuonc/nou109. Epub 2014 Jun 20. Review.

11.

Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.

Xie P, Lefrançois P.

J Am Acad Dermatol. 2018 Dec;79(6):1089-1100.e17. doi: 10.1016/j.jaad.2018.07.004. Epub 2018 Jul 10.

PMID:
30003981
12.

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.

Danial C, Sarin KY, Oro AE, Chang AL.

Clin Cancer Res. 2016 Mar 15;22(6):1325-9. doi: 10.1158/1078-0432.CCR-15-1588. Epub 2015 Nov 6.

13.

Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.

Katoh M.

Clin Sci (Lond). 2019 Apr 29;133(8):953-970. doi: 10.1042/CS20180845. Print 2019 Apr 30. Review.

PMID:
31036756
14.

Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib.

Lou E, Schomaker M, Wilson JD, Ahrens M, Dolan M, Nelson AC.

Cancer Biol Ther. 2016 Oct 2;17(10):1010-1016. doi: 10.1080/15384047.2016.1220453. Epub 2016 Sep 29.

15.

A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.

Pak E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, Park PMC, Wu L, Shaw DL, Addleson EC, Cayer SS, Lopez BG, Agar NYR, Rubin LL, Qi J, Merk DJ, Segal RA.

Neuro Oncol. 2019 May 16. pii: noz089. doi: 10.1093/neuonc/noz089. [Epub ahead of print]

PMID:
31111916
16.

Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.

Coni S, Mancuso AB, Di Magno L, Sdruscia G, Manni S, Serrao SM, Rotili D, Spiombi E, Bufalieri F, Petroni M, Kusio-Kobialka M, De Smaele E, Ferretti E, Capalbo C, Mai A, Niewiadomski P, Screpanti I, Di Marcotullio L, Canettieri G.

Sci Rep. 2017 Mar 9;7:44079. doi: 10.1038/srep44079. Erratum in: Sci Rep. 2017 Apr 21;7:46645.

17.

A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.

Buetti-Dinh A, Jensen R, Friedman R.

BMC Cancer. 2018 May 18;18(1):569. doi: 10.1186/s12885-018-4451-1.

18.

Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.

Lou E, Nelson AC, Kool M.

Cancer Biol Ther. 2019;20(11):1398-1402. doi: 10.1080/15384047.2019.1647057. Epub 2019 Aug 18.

PMID:
31423907
19.

Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors.

Geyer N, Ridzewski R, Bauer J, Kuzyakova M, Dittmann K, Dullin C, Rosenberger A, Schildhaus HU, Uhmann A, Fulda S, Hahn H.

Front Oncol. 2018 Sep 25;8:396. doi: 10.3389/fonc.2018.00396. eCollection 2018.

20.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).

Invest New Drugs. 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20.

PMID:
28317088

Supplemental Content

Support Center